Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
14.05. | CDMO Famar expands reach in Europe with acquisition of sterile manufacturing plant in Germany | ||
13.05. | Organon taps into 'romantasy' craze with new Nexplanon ad | ||
13.05. | As Bayer's restructuring rolls on, Kerendia and Nubeqa power pharma unit to surprising sales increase | ||
13.05. | Roche spotlights Perjeta's staying power with 10-year breast cancer survival results | ||
13.05. | Ratio inks deal to build radiopharmaceutical R&D, manufacturing facility in Utah | ||
13.05. | Mayne hit by misleading drug safety claims from the FDA ahead of $430M buyout | ||
13.05. | Bluebird bio warns of potential bankruptcy after another buyout delay | ||
13.05. | Novo heads to regulators after Sogroya matches predecessor Norditropin in 3 pediatric growth disorders | ||
12.05. | Madrigal touts biomarker data in key MASH population as it works to grow Rezdiffra's reach | ||
12.05. | Medtronic activates Star power, tapping TV personality to get women discussing heart health | ||
12.05. | Trump signs sweeping executive order to cut US drug prices by 'up to 90%' | ||
12.05. | Pfizer partner RemeGen says HER2 ADC prolongs life in newly diagnosed bladder cancer | ||
12.05. | Roche gets to work on US investment plan with reveal of $700M obesity drug plant in North Carolina | ||
12.05. | AbbVie remains king in doctors' perception of immunology drugmakers, but J&J regains some ground | ||
12.05. | FDA, CDC call for pause of chikungunya shot rollout in older adults | ||
12.05. | Abeona nets $155M with FDA voucher sale just 2 weeks after gene therapy approval | ||
09.05. | Verastem scores FDA nod for first-of-its-kind oral combination to treat rare form of ovarian cancer | ||
09.05. | AstraZeneca opens the door to Imfinzi expansion with trial win in high-risk bladder cancer patients | ||
09.05. | Roche pledges nearly $300M to establish new Vabysmo production plant in China | ||
08.05. | Argenx brews up DTC push for Vyvgart Hytrulo prefilled syringe in generalized myasthenia gravis | ||
08.05. | FDA misses another approval decision target date, this time for GSK's Nucala in COPD | ||
08.05. | In first oncology expert meeting under Makary, FDA spotlights cancer drugs from J&J, Pfizer, Roche and UroGen | ||
08.05. | Trump to sign 'most favored nation' executive order to slash drug prices for Medicare: Politico | ||
08.05. | Takeda looks toward 'inflection point' as it eyes new launches to shake off Vyvanse generic impacts | ||
08.05. | Amneal bolsters US manufacturing capacity with Apiject collaboration deal |